- Home
- KAVL vs PRPO Comparison
KAVL vs PRPO Comparison
Compare KAVL & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- PRPO
- Stock Information
- Founded
- KAVL 1998
- PRPO N/A
- Country
- KAVL United States
- PRPO United States
- Employees
- KAVL N/A
- PRPO N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- KAVL Health Care
- PRPO Industrials
- Exchange
- KAVL Nasdaq
- PRPO Nasdaq
- Market Cap
- KAVL 11.4M
- PRPO 12.3M
- IPO Year
- KAVL N/A
- PRPO N/A
- Fundamental
- Price
- KAVL $0.94
- PRPO $10.14
- Analyst Decision
- KAVL
- PRPO
- Analyst Count
- KAVL 0
- PRPO 0
- Target Price
- KAVL N/A
- PRPO N/A
- AVG Volume (30 Days)
- KAVL 379.3K
- PRPO 13.1K
- Earning Date
- KAVL 02-10-2025
- PRPO 03-28-2025
- Dividend Yield
- KAVL N/A
- PRPO N/A
- EPS Growth
- KAVL N/A
- PRPO N/A
- EPS
- KAVL N/A
- PRPO N/A
- Revenue
- KAVL $6,886,665.00
- PRPO $17,411,000.00
- Revenue This Year
- KAVL N/A
- PRPO $75.18
- Revenue Next Year
- KAVL N/A
- PRPO N/A
- P/E Ratio
- KAVL N/A
- PRPO N/A
- Revenue Growth
- KAVL N/A
- PRPO 31.31
- 52 Week Low
- KAVL $0.58
- PRPO $4.31
- 52 Week High
- KAVL $9.69
- PRPO $10.74
- Technical
- Relative Strength Index (RSI)
- KAVL 38.29
- PRPO 85.00
- Support Level
- KAVL $0.93
- PRPO $7.02
- Resistance Level
- KAVL $1.49
- PRPO $7.54
- Average True Range (ATR)
- KAVL 0.13
- PRPO 0.50
- MACD
- KAVL -0.06
- PRPO 0.29
- Stochastic Oscillator
- KAVL 3.27
- PRPO 85.72
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.